The earnings call presented a company in transition, highlighting strong growth prospects for LOQTORZI and promising clinical developments. However, challenges in market penetration and short-term revenue impacts due to restructuring were noted. Despite these challenges, the strategic focus on oncology and potential cost savings are positive indicators for future performance.

Company Guidance -

Q2 2025

During the Coherus BioSciences Q1 2025 earnings call, key guidance focused on the company's strategic shift to an innovative oncology business, highlighted by the FDA-approved PD-1 inhibitor LOQTORZI. The company projects LOQTORZI sales in nasopharyngeal carcinoma (NPC) to grow to $150 million to $200 million annually over the next three years, with a breakeven point of $15 million per quarter to cover commercial costs. Coherus is executing an indication expansion strategy for LOQTORZI, with multiple partnerships and pivotal trials in place to broaden its use across different cancer types. The call also emphasized the ongoing development of CHS-114 and casdozokitug, with clinical data readouts expected in 2025 supporting the advancement of these candidates. The company anticipates annualized savings of $25 million from headcount reductions following the UDENYCA divestiture and projects SG&A expenses for 2025 to be between $90 million and $100 million.

LOQTORZI Growth Prospects

LOQTORZI is projected to grow to about $150 million to $200 million annually over the next three years, providing non-dilutive funding for the development pipeline and becoming an important revenue source as indications expand.

Positive Clinical Developments

CHS-114 showed a 40% reduction in target lesions in a late-line head and neck cancer patient, indicating potential to address PD-1 resistance. Additionally, a 17% complete response rate was observed in a liver cancer trial with casdozokitug.

Strategic Partnerships and Indication Expansion

Several agreements are in place to expand indications for toripalimab, including collaborations with INOVIO for HPV-positive head and neck cancer, and Junshi for small cell lung cancer.

Successful Restructuring and Cost Savings

The company expects $25 million in annualized savings from a reduced headcount post-UDENYCA divestiture, with more than half already realized.

Coherus Biosciences (CHRS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CHRS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2025 (Q2)	-0.22 / -	-0.11	―	―	―
May 12, 2025	2025 (Q1)	-0.30 / -0.41	0.83	-149.40% (-1.24)	―
Mar 10, 2025	2024 (Q4)	-0.31 / -0.44	-0.71	38.03% (+0.27)	―
Nov 06, 2024	2024 (Q3)	-0.16 / -0.09	-0.41	78.05% (+0.32)	―
Aug 08, 2024	2024 (Q2)	-0.25 / -0.11	-0.49	77.55% (+0.38)	―
May 09, 2024	2024 (Q1)	-0.25 / 0.83	-0.96	186.46% (+1.79)	―
Mar 13, 2024	2023 (Q4)	-0.20 / -0.71	-0.76	6.58% (+0.05)	―
Nov 06, 2023	2023 (Q3)	-0.39 / -0.41	-1.11	63.06% (+0.70)	―
Aug 02, 2023	2023 (Q2)	-0.63 / -0.49	-0.65	24.62% (+0.16)	―
May 08, 2023	2023 (Q1)	-0.72 / -0.96	-1.24	22.58% (+0.28)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CHRS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 12, 2025	$1.02	$0.82	-19.61%
Mar 10, 2025	$1.04	$1.05	+0.96%
Nov 06, 2024	$0.72	$0.82	+13.89%
Aug 08, 2024	$1.29	$1.43	+10.85%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Coherus Biosciences (CHRS) report earnings?

Coherus Biosciences (CHRS) is schdueled to report earning on Aug 07, 2025, After Close (Confirmed).

What is Coherus Biosciences (CHRS) earnings time?

Coherus Biosciences (CHRS) earnings time is at Aug 07, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CHRS EPS forecast?

CHRS EPS forecast for the fiscal quarter 2025 (Q2) is -0.22.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing